The role of endothelin receptor antagonists in cardiovascular pharmacotherapy

Emerging Drugs

Volumn 6, Issue 1, 2001, Pages 3-11

  Munter K ^a   Kirchengast, M ^a  

^a Knoll AG   (Germany)

Author keywords

ABT 627; Atrasentan; BMS 193884; Bosentan; Congestive heart failure; Darusentan; Endothelin receptor antagonists; Enrasentan; Hypertension; LU 135252; Pulmonary hypertension; Ro 47 0203; Ro 61 0612; SB 217242; Sitaxsentan; TBC 11251, tezosentan

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; AMBRISENTAN; ATRASENTAN; BMS 193884; BOSENTAN; BSF 420627; DARUSENTAN; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; RECEPTOR SUBTYPE; SITAXSENTAN; TBC 11252; TEZOSENTAN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FLUSHING; HEADACHE; HEART FAILURE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; LEG EDEMA; NONHUMAN; PULMONARY HYPERTENSION; REVIEW;

EID: 0035032129     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.1.3     Document Type: Review

References (60)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology
3. Endothelins and endothelin receptor antagonists
4. Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine
5. B receptors
6. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
7. Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo
8. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men
9. B receptors
10. Endothelin-A receptor antagonist mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
11. Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs
12. Growth factor activity of endothelin on vascular smooth muscle
13. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension
14. A receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans
15. Endothelin in hypertension: A role for receptor antagonists?
16. Role of endothelin-1 in hypertension
17. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats
18. A receptor antagonist: LU 135252
19. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats
20. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension
21. Regulation of plasma endothelin by salt in salt-sensitive hypertension
22. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
23. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
24. Oral sitaxsentan and endothelin-a selective receptor antagonist, reduces systemic blood pressure in patients with mild-to-moderate primary hypertension
25. Update of REACH-1 and MERIT-HF clinical trials in heart failure
26. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition
27. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure
28. Maintenance of blood pressure in normotensive dogs by endothelin-1
29. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with sympatomatic severe chronic heart failure
30. Physiological significance of endothelin. Its role in congestive heart failure
31. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine induced heart failure
32. Endothelin in human congestive heart failure
33. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction
34. A receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
35. Beneficial hemodynamic effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure
36. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
37. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure
38. B receptor antagonists in congestive heart failure
39. Chronic oral endothelin Type A receptor antagonism in experimental heart failure
40. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling
41. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure
42. A receptor blockade in patients with congestive heart failure
43. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
44. Acute and short term effects of the non-peptide endothelin-1 receptor antagonist bosentan in humans
45. A receptor blockade trial)
46. Multicenter, double-blind, placebo controlled study of long-term endothelin blockade with bosentan in chronic heart failure- Results of the REACH-1 trial
47. Endothelins and the lung
48. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics
49. A receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy) -3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats
50. A receptor antagonist LU 135252 prevents the progression of established pulmonary hypertension induced by monocrotaline in rats
51. LU 135252, an endothelinA receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction
52. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
53. Bosentan, a dual endothelin receptor antagonist, improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension: Results of a double blind, randomized, placebo-controlled trial
54. Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker sitaxsentan in pulmonary arterial hypertension
55. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure
56. Endothelin blockade inhibits atherosclerosis and restores endothelial function
57. Targets for endothelin in the diseased kidney: Clues for therapeutic intervention
58. Endothelin antagonists in renal disease
59. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1
60. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits